Jazz Pharmaceuticals plc Quarterly Net Income (Loss) Attributable to Parent in USD from Q1 2010 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Summary
Jazz Pharmaceuticals plc quarterly/annual Net Income (Loss) Attributable to Parent history and growth rate from Q1 2010 to Q2 2024.
  • Jazz Pharmaceuticals plc Net Income (Loss) Attributable to Parent for the quarter ending June 30, 2024 was $169M, a 61.4% increase year-over-year.
  • Jazz Pharmaceuticals plc Net Income (Loss) Attributable to Parent for the twelve months ending June 30, 2024 was $395M.
  • Jazz Pharmaceuticals plc annual Net Income (Loss) Attributable to Parent for 2023 was $415M.
  • Jazz Pharmaceuticals plc annual Net Income (Loss) Attributable to Parent for 2022 was -$224M, a 32% increase from 2021.
  • Jazz Pharmaceuticals plc annual Net Income (Loss) Attributable to Parent for 2021 was -$330M, a 238% decline from 2020.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q2 2024 $395M $169M +$64.1M +61.4% Apr 1, 2024 Jun 30, 2024 10-Q 2024-08-01
Q1 2024 $331M -$14.6M -$84M -121% Jan 1, 2024 Mar 31, 2024 10-Q 2024-08-01
Q4 2023 $415M $94.2M +$335M Oct 1, 2023 Dec 31, 2023 10-K 2024-02-28
Q3 2023 $80M $147M +$166M Jul 1, 2023 Sep 30, 2023 10-Q 2023-11-08
Q2 2023 -$86.5M $104M +$69.8M +201% Apr 1, 2023 Jun 30, 2023 10-Q 2024-08-01
Q1 2023 -$156M $69.4M +$67.8M +4115% Jan 1, 2023 Mar 31, 2023 10-Q 2024-08-01
Q4 2022 -$224M -$241M -$205M -581% Oct 1, 2022 Dec 31, 2022 10-K 2024-02-28
Q3 2022 -$18.7M -$19.6M +$33.2M +62.8% Jul 1, 2022 Sep 30, 2022 10-Q 2023-11-08
Q2 2022 -$51.9M $34.7M +$398M Apr 1, 2022 Jun 30, 2022 10-Q 2023-11-08
Q1 2022 -$450M $1.65M -$120M -98.6% Jan 1, 2022 Mar 31, 2022 10-Q 2023-11-08
Q4 2021 -$330M -$35.4M -$169M -126% Oct 1, 2021 Dec 31, 2021 10-K 2024-02-28
Q3 2021 -$161M -$52.8M -$201M -136% Jul 1, 2021 Sep 30, 2021 10-Q 2022-11-09
Q2 2021 $40.2M -$363M -$478M -416% Apr 1, 2021 Jun 30, 2021 10-Q 2022-11-09
Q1 2021 $518M $122M +$280M Jan 1, 2021 Mar 31, 2021 10-Q 2022-11-09
Q4 2020 $239M $133M +$59.4M +80.3% Oct 1, 2020 Dec 31, 2020 10-K 2021-02-23
Q3 2020 $179M $148M +$46M +44.9% Jul 1, 2020 Sep 30, 2020 10-Q 2021-11-09
Q2 2020 $133M $115M -$147M -56.2% Apr 1, 2020 Jun 30, 2020 10-Q 2021-11-09
Q1 2020 $280M -$158M -$243M -285% Jan 1, 2020 Mar 31, 2020 10-Q 2021-11-09
Q4 2019 $523M $74M -$85.5M -53.6% Oct 1, 2019 Dec 31, 2019 10-K 2021-02-23
Q3 2019 $609M $102M -$47M -31.5% Jul 1, 2019 Sep 30, 2019 10-K 2021-02-23
Q2 2019 $656M $262M +$170M +184% Apr 1, 2019 Jun 30, 2019 10-K 2021-02-23
Q1 2019 $486M $85.2M +$39.2M +85.3% Jan 1, 2019 Mar 31, 2019 10-K 2021-02-23
Q4 2018 $447M $159M -$72.7M -31.3% Oct 1, 2018 Dec 31, 2018 10-K 2020-02-25
Q3 2018 $520M $149M +$85.8M +135% Jul 1, 2018 Sep 30, 2018 10-K 2020-02-25
Q2 2018 $434M $92.3M -$13.3M -12.6% Apr 1, 2018 Jun 30, 2018 10-K 2020-02-25
Q1 2018 $447M $46M -$40.5M -46.8% Jan 1, 2018 Mar 31, 2018 10-K 2020-02-25
Q4 2017 $488M $232M +$116M +99% Oct 1, 2017 Dec 31, 2017 10-K 2019-02-26
Q3 2017 $372M $63.5M -$26.3M -29.3% Jul 1, 2017 Sep 30, 2017 10-K 2019-02-26
Q2 2017 $399M $106M -$8.9M -7.77% Apr 1, 2017 Jun 30, 2017 10-K 2019-02-26
Q1 2017 $408M $86.5M +$10.7M +14.1% Jan 1, 2017 Mar 31, 2017 10-K 2019-02-26
Q4 2016 $397M $117M +$33.9M +41% Oct 1, 2016 Dec 31, 2016 10-K 2018-02-27
Q3 2016 $363M $89.8M +$1.87M +2.12% Jul 1, 2016 Sep 30, 2016 10-K 2018-02-27
Q2 2016 $361M $115M +$26.4M +29.9% Apr 1, 2016 Jun 30, 2016 10-K 2018-02-27
Q1 2016 $335M $75.8M +$5.11M +7.23% Jan 1, 2016 Mar 31, 2016 10-K 2018-02-27
Q4 2015 $330M $82.8M +$1.15M +1.41% Oct 1, 2015 Dec 31, 2015 10-K 2017-02-28
Q3 2015 $328M $88M +$62.2M +241% Jul 1, 2015 Sep 30, 2015 10-K 2017-02-28
Q2 2015 $266M $88.1M +$44.5M +102% Apr 1, 2015 Jun 30, 2015 10-K 2017-02-28
Q1 2015 $222M $70.7M +$163M Jan 1, 2015 Mar 31, 2015 10-K 2017-02-28
Q4 2014 $58.4M $81.6M +$26.3M +47.6% Oct 1, 2014 Dec 31, 2014 10-K 2016-02-23
Q3 2014 $32.1M $25.8M -$49.6M -65.8% Jul 1, 2014 Sep 30, 2014 10-K 2016-02-23
Q2 2014 $81.7M $43.7M +$1.47M +3.49% Apr 1, 2014 Jun 30, 2014 10-K 2016-02-23
Q1 2014 $80.2M -$92.7M -$136M -313% Jan 1, 2014 Mar 31, 2014 10-K 2016-02-23
Q4 2013 $216M $55.3M -$145M -72.4% Oct 1, 2013 Dec 31, 2013 10-K 2015-02-24
Q3 2013 $362M $75.4M +$42.2M +127% Jul 1, 2013 Sep 30, 2013 10-K 2015-02-24
Q2 2013 $319M $42.2M +$15M +55.4% Apr 1, 2013 Jun 30, 2013 10-K 2015-02-24
Q1 2013 $304M $43.4M +$15.7M +56.9% Jan 1, 2013 Mar 31, 2013 10-K 2015-02-24
Q4 2012 $289M $201M +$163M +435% Oct 1, 2012 Dec 31, 2012 10-K 2014-02-25
Q3 2012 $126M $33.2M +$727K +2.24% Jul 1, 2012 Sep 30, 2012 10-K 2014-02-25
Q2 2012 $125M $27.1M -$6.06M -18.2% Apr 1, 2012 Jun 30, 2012 10-K 2014-02-25
Q1 2012 $131M $27.7M +$5.85M +26.8% Jan 1, 2012 Mar 31, 2012 10-K 2014-02-25
Q4 2011 $125M $37.5M $0 0% Oct 1, 2011 Dec 31, 2011 10-K 2012-02-28
Q3 2011 $125M $32.5M $0 0% Jul 1, 2011 Sep 30, 2011 10-Q 2012-11-09
Q2 2011 $125M $33.2M $0 0% Apr 1, 2011 Jun 30, 2011 10-Q 2012-08-07
Q1 2011 $125M $21.8M $0 0% Jan 1, 2011 Mar 31, 2011 10-Q 2012-05-08
Q4 2010 $125M $37.5M Oct 1, 2010 Dec 31, 2010 10-K 2013-02-26
Q3 2010 $32.5M Jul 1, 2010 Sep 30, 2010 10-K 2013-02-26
Q2 2010 $33.2M Apr 1, 2010 Jun 30, 2010 10-K 2013-02-26
Q1 2010 $21.8M Jan 1, 2010 Mar 31, 2010 10-K 2013-02-26
* An asterisk sign (*) next to the value indicates that the value is likely invalid.